Compare Quest Diagnostics Inc (DGX) vs iShares Core MSCI EAFE ETF (IEFA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs iShares Core MSCI EAFE ETF — how do they compare? Quest Diagnostics Inc trades at $230.76 (market cap $25.48B), while iShares Core MSCI EAFE ETF trades at $96.33 (market cap $189.19B). The key difference: iShares Core MSCI EAFE ETF is far larger — about 7.4× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while iShares Core MSCI EAFE ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and iShares Core MSCI EAFE ETF for 40 Days on average.
| DGX | IEFA | |
|---|---|---|
Market Cap | $25.48B | $189.19B |
Volume | 941,866 | 8,441,787 |
Sector | Health | Broad Market / Factor |
52-Week High | $247.45 | $101.41 |
52-Week Low | $173.49 | $85.06 |
Typical Hold Time | 56 Days | 40 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
IEFA trades at $96.18, down 0.02% on the day, with a bearish technical outlook indicated by moving averages and oscillators. The ETF, managed by BlackRock, holds $196 billion in assets and focuses on developed markets outside North America. Recent news highlights comparisons with competing international ETFs, noting its higher dividend yield and lower expense ratio relative to some peers, though performance has lagged behind certain total-world and emerging market funds over the past year.
The outlook for IEFA is clouded by technical weakness and competitive pressures, though its scale and cost efficiency offer stability. Key risks include concentration in developed markets, which may underperform during global growth shifts, and the impact of geopolitical tensions on international equities. Analyst sentiment is mixed, with the fund's defensive characteristics balancing against limited near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →
